Scholarlink

Background <p>This study aimed to investigate the role of <i>miR-218-5p</i> and CKLF-like marvel transmembrane domain-containing 3 (CMTM3) and the interaction between them in glioma.</p> Methods <p>The presence of CMTM3 in glioma cells and tissues was detected using immunohistochemical analysis, quantitative reverse transcription polymerase chain reaction, and western blotting. Public databases were used to examine the relationship between CMTM3 expression and patient survival. Transwell assay was performed to evaluate the invasive potential of glioma cells with downregulated CMTM3. Luciferase reporter assay was performed to validate the role of <i>miR-218-5p</i> in regulating CMTM3 expression. Intracranial xenograft models were established to investigate the role of CMTM3 in glioma in vivo.</p> Results <p>CMTM3 was upregulated in glioma cells and tissues. Higher CMTM3 expression was significantly associated with shorter overall survival and more advanced clinicopathological characteristics in patients with glioma. Functional assays demonstrated that downregulation of CMTM3 potently suppressed the proliferative and invasive abilities of glioma cells in vitro and reduced tumor growth by approximately 66% in an intracranial xenograft model. Transfection with a <i>miR-218-5p</i> mimic suppressed CMTM3 expression by approximately 68% at the mRNA level and 70% at the protein level in glioma cell lines, indicating that CMTM3 was directly regulated by <i>miR-218-5p</i>. Additionally, the <i>miR-218-5p</i> mimic significantly inhibited the proliferative and invasive abilities of glioma cells.</p> Conclusion <p><i>MiR-218-5p</i> regulates the oncogenic role of CMTM3 in glioma. Therefore, targeting the <i>miR-218-5p</i>/CMTM3 axis is a promising therapeutic strategy for glioma.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

MiR-218-5p inhibits glioma progression by targeting CKLF-like MARVEL transmembrane domain-containing 3

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年1月12日

查看全文
  • Xiangying Li,
  • Ting Lu,
  • Tong Wang,
  • Jianwei Zhuo,
  • Zhengquan Yu,
  • Gang Cui,
  • Haitao Shen

摘要

Background

This study aimed to investigate the role of miR-218-5p and CKLF-like marvel transmembrane domain-containing 3 (CMTM3) and the interaction between them in glioma.

Methods

The presence of CMTM3 in glioma cells and tissues was detected using immunohistochemical analysis, quantitative reverse transcription polymerase chain reaction, and western blotting. Public databases were used to examine the relationship between CMTM3 expression and patient survival. Transwell assay was performed to evaluate the invasive potential of glioma cells with downregulated CMTM3. Luciferase reporter assay was performed to validate the role of miR-218-5p in regulating CMTM3 expression. Intracranial xenograft models were established to investigate the role of CMTM3 in glioma in vivo.

Results

CMTM3 was upregulated in glioma cells and tissues. Higher CMTM3 expression was significantly associated with shorter overall survival and more advanced clinicopathological characteristics in patients with glioma. Functional assays demonstrated that downregulation of CMTM3 potently suppressed the proliferative and invasive abilities of glioma cells in vitro and reduced tumor growth by approximately 66% in an intracranial xenograft model. Transfection with a miR-218-5p mimic suppressed CMTM3 expression by approximately 68% at the mRNA level and 70% at the protein level in glioma cell lines, indicating that CMTM3 was directly regulated by miR-218-5p. Additionally, the miR-218-5p mimic significantly inhibited the proliferative and invasive abilities of glioma cells.

Conclusion

MiR-218-5p regulates the oncogenic role of CMTM3 in glioma. Therefore, targeting the miR-218-5p/CMTM3 axis is a promising therapeutic strategy for glioma.